Overview

Sublingual Methadone for the Management of Cancer Breakthrough Pain

Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
A dose titration protocol for sublingual methadone hydrochloride for the management of cancer-related breakthrough pain to find the optimal dose.
Phase:
Phase 1
Details
Lead Sponsor:
AHS Cancer Control Alberta
Alberta Health Services
Collaborator:
Calgary Health Region
Treatments:
Methadone